| Identification | Back Directory | [Name]
4-Pyrimidinamine, N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-(4-morpholinyl)- | [CAS]
2167246-24-2 | [Synonyms]
CAD-1883
Rimtuzalcap
Rimtuzalcap(CAD-1883)
4-Pyrimidinamine, N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-(4-morpholinyl)-
KcsA,movement,small-conductance,channels,Rimtuzalcap,SK channels,CAD1883,CAD 1883,tremor,Potassium Channel,essential,inhibit,spinocerebellar,potassium,ataxia,SCA,Inhibitor,disorders,calcium-activated | [Molecular Formula]
C18H24F2N6O | [MOL File]
2167246-24-2.mol | [Molecular Weight]
378.42 |
| Chemical Properties | Back Directory | [Boiling point ]
618.0±65.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 250 mg/mL (660.64 mM; Need ultrasonic) | [form ]
Solid | [pka]
3.62±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA)[1]. | [in vivo]
Rimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 μM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice[1]. | [storage]
4°C, protect from light | [References]
[1] Crystalline forms of potassium channel modulators. WO2020086456A1. |
|
|